Update re. investment in Conduit Pharmaceuticals
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your CHP notes
The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. ("Conduit") on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments.
Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit's issued share capital. At the closing mid-market price of $0.17 on 8 August 2024, Vela's holding in Conduit is valued at approximately $170,000.
| The full release from Conduit can be accessed here (Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments | Nasdaq) and is re-produced in full below. |
About Reach announcements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.